Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of New York Mellon Corp (BNY) vs GeneDx Holdings Corp (WGS) Price & Performance

Bank of New York Mellon CorpTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Bank of New York Mellon Corp vs GeneDx Holdings Corp — how do they compare? Bank of New York Mellon Corp trades at $158.75 (market cap $106.05B), while GeneDx Holdings Corp trades at $62.68 (market cap $1.85B). The key difference: Bank of New York Mellon Corp is far larger — about 57.3× GeneDx Holdings Corp's market cap, and Bank of New York Mellon Corp pays a 1.37% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

BNYWGS
Market Cap
$106.05B$1.85B
Sector
FinancialsTechnology
52-Week High
$154.50$167.51
52-Week Low
$95.16$34.51
Dividend Yield
1.37%
Enterprise Value
$1.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of New York Mellon Corp

BNY trades at $151.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue growth has been steady, rising from $16.0B in 2022 to $19.8B in 2025, while net income margin improved to 29.21%. Analyst consensus is mixed with 38% buy ratings but a $156 price target suggesting modest upside. Recent news highlights strong fee income expectations and a planned 19% dividend increase.

BNY demonstrates solid fundamental strength with improving profitability and consistent earnings beats. The stock offers potential upside to analyst targets and dividend growth, but faces risks from high investing cash outflows and competitive pressures. Current valuation metrics appear reasonable relative to historical performance, though investors should monitor Q2 earnings results for confirmation of growth trajectory.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.

Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bank of New York Mellon Corp

BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.

Read more on BNY

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS